Skip to main content

Automated nucleic acid amplification assay for mycoplasma detection in Cell and Gene therapy products

This content was first published by European Pharmaceutical Review (EPR).

Author: Ambili Menon, PhD, Sr. Staff Scientist, Pharma Quality Control, bioMérieux Inc., Lombard, IL, USA.

Ambili Menon, Pharma Quality Control, bioMérieux Inc. addresses the task of microbiological testing for advanced therapeutic medicinal products.

Download the White Paper

Complete the form below to access the white paper, which will be sent directly to your email after submission. By providing your information, you agree to receive additional emails from bioMérieux about Mycoplasma testing. 

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.

   

RELATED CONTENT

BIOFIRE MYCOPLASMA

Easy 1 Hour Mycoplasma Detection in Cell Therapy Samples

Various pharmacopoeias, including the USP, specify a test for mycoplasma contamination must be performed as part of the release testing of a product manufactured in the presence of eukaryotic cells.

READ MORE

Overcoming Mycoplasma Testing Challenges in Cell and gene Therapy Manufacturing with BIOFIRE®

The BIOFIRE® Mycoplasma test is a closed-system sample-to-answer nucleic acid test that is designed to report the presence/absence of over 130 mycoplasma species in less than an hour. It requires minimal hands-on time and contains everything needed to run a molecular test in a sealed pouch.

READ MORE

BIOFIRE® Mycoplasma

BIOFIRE® Mycoplasma provides simple, accurate, and rapid in-house mycoplasma detection for use in testing raw materials, in-process samples, and final product release. We offer validation services designed to meet regulatory requirements—from documentation to comprehensive on-site support.

READ MORE